Merrimack Pharmaceuticals, Inc. (MACK)

NASDAQ: MACK · IEX Real-Time Price · USD
12.62
-0.05 (-0.43%)
At close: Jun 2, 2023, 4:00 PM
12.89
+0.28 (2.18%)
After-hours: Jun 2, 2023, 4:22 PM EDT
-0.43%
Market Cap 179.89M
Revenue (ttm) n/a
Net Income (ttm) -1.68M
Shares Out 14.26M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 56,339
Open 12.68
Previous Close 12.67
Day's Range 12.55 - 12.69
52-Week Range 3.00 - 13.66
Beta 1.80
Analysts n/a
Price Target n/a
Earnings Date May 4, 2023

About MACK

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 29, 2012
Country United States
Stock Exchange NASDAQ
Ticker Symbol MACK
Full Company Profile

Financial Performance

Financial Statements

News

Merrimack College Teacher Survey Highlights Troubling K-12 Teacher Morale Issues

NORTH ANDOVER, Mass.--(BUSINESS WIRE)--A newly released study shines a spotlight on a pressing crisis facing American education: Only 46% of current public K-12 educators would be “fairly” or “very li...

2 weeks ago - Business Wire

Merrimack Reports First Quarter 2023 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2023 financial results for the period ended March 3...

1 month ago - Business Wire

Merrimack Reports Full Year 2022 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2022 financial results for the period ended December 31, ...

3 months ago - Business Wire
}

Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “Company” or “Merrimack”), announced today that its Board of Directors (the “Board”) has extended the Section 3...

6 months ago - Business Wire

Merrimack stock rockets 200% after positive trial data on Onivyde pancreatic cancer treatment

Shares of Merrimack Pharmaceuticals Inc. MACK, +224.14% skyrocketed 199.5% toward a 4 1/2-year high in morning trading Wednesday, after the France-based biopharmaceutical company Ipsen IPSEY, +1.39% I...

7 months ago - Market Watch

Merrimack Reports Third Quarter 2022 Financial Results

CAMBRIDGE, Mass.

7 months ago - Business Wire

Merrimack Reports Second Quarter 2022 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Second Quarter 2022 Financial Results

10 months ago - Business Wire
}

Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Provides Ipsen report of results from Phase III RESILIENT trial evaluating Onivyde® in second-line monotherapy for small cell lung cancer

10 months ago - Business Wire

Merrimack Reports First Quarter 2022 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2022 financial results for the period ended March 3...

1 year ago - Business Wire

Merrimack Reports Full Year 2021 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2021 Financial Results

1 year ago - Business Wire

Merrimack Reports Third Quarter 2021 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals Reports Third Quarter 2021 Financial Results

1 year ago - Business Wire

Merrimack Reports Second Quarter 2021 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) (“Merrimack” or the “Company”) today announced its second quarter 2021 financial results for the period ended June 30, ...

1 year ago - Business Wire
}

Merrimack Reports Full Year 2020 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2020 Financial Results

2 years ago - Business Wire

Merrimack Reports Third Quarter 2020 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals Q3 2020 Earnings Release

2 years ago - Business Wire

Merrimack Reports Second Quarter 2020 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Second Quarter 2020 Financial Results

3 years ago - Business Wire